Evaluating the Efficacy and Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Evaluating the Efficacy and Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) causes end-stage renal disease (ESRD) and a decline in the estimated glomerular filtration rate (eGFR) (1,2). In this meta-analysis, we aimed to assess the efficacy and safety of tolvaptan in delaying both eGFR decline and total kidney...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed Ibrahim, Ibrahim Nagmeldin Hassan, Ahmed Mohammed Alhassan Ismail Abdulsamad
Format: Article
Language:English
Published: University Library System, University of Pittsburgh 2025-01-01
Series:International Journal of Medical Students
Subjects:
Autosomal dominant polycystic kidney disease (ADPKD)
Tolvaptan
eGFR (estimated glomerular filtration rate)
TKV (total kidney volume)
Online Access:http://ijms.info/IJMS/article/view/2968
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items